Your browser doesn't support javascript.
loading
Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma.
Xiang, Handan; Pan, Yidan; Sze, Marc A; Wlodarska, Marta; Li, Ling; van de Mark, Karyn Ann; Qamar, Haleema; Moure, Casey J; Linn, Douglas E; Hai, Josephine; Huo, Ying; Clarke, James; Tan, Tze Guan; Ho, Samantha; Teng, Karen W; Ramli, Muhammad N; Nebozhyn, Michael; Zhang, Chunsheng; Barlow, Julianne; Gustafson, Corinne E; Gornisiewicz, Savanna; Albertson, Thomas P; Korle, Stephanie L; Bueno, Raphael; Moy, Lily Y; Vollmann, Elisabeth H; Chiang, Derek Y; Brandish, Philip E; Loboda, Andrey.
Affiliation
  • Xiang H; Discovery Immunology, Merck & Co., Inc., Cambridge, Massachusetts.
  • Pan Y; Data and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.
  • Sze MA; Data and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.
  • Wlodarska M; Discovery Oncology, Merck & Co., Inc., Boston, Massachusetts.
  • Li L; Quantitative Bioscience, MSD, Singapore.
  • van de Mark KA; Discovery Immunology, Merck & Co., Inc., Cambridge, Massachusetts.
  • Qamar H; Discovery Immunology, Merck & Co., Inc., Cambridge, Massachusetts.
  • Moure CJ; Discovery Oncology, Merck & Co., Inc., Boston, Massachusetts.
  • Linn DE; Quantitative Bioscience, Merck & Co., Inc., Boston, Massachusetts.
  • Hai J; Quantitative Bioscience, Merck & Co., Inc., Boston, Massachusetts.
  • Huo Y; Quantitative Bioscience, Merck & Co., Inc., Boston, Massachusetts.
  • Clarke J; Data and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.
  • Tan TG; Discovery Cardiometabolic Diseases, MSD, Singapore.
  • Ho S; Discovery Cardiometabolic Diseases, MSD, Singapore.
  • Teng KW; Discovery Cardiometabolic Diseases, MSD, Singapore.
  • Ramli MN; Quantitative Bioscience, MSD, Singapore.
  • Nebozhyn M; Data and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.
  • Zhang C; Data and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.
  • Barlow J; The Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Gustafson CE; The Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Gornisiewicz S; The Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Albertson TP; The Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Korle SL; The Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Bueno R; The Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Moy LY; Quantitative Bioscience, Merck & Co., Inc., Boston, Massachusetts.
  • Vollmann EH; Discovery Immunology, Merck & Co., Inc., Cambridge, Massachusetts.
  • Chiang DY; Data and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.
  • Brandish PE; Discovery Oncology, Merck & Co., Inc., Boston, Massachusetts.
  • Loboda A; Data and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.
Cancer Res ; 84(9): 1410-1425, 2024 May 02.
Article in En | MEDLINE | ID: mdl-38335304
ABSTRACT
Cancer immunotherapy has revolutionized the treatment of lung adenocarcinoma (LUAD); however, a significant proportion of patients do not respond. Recent transcriptomic studies to understand determinants of immunotherapy response have pinpointed stromal-mediated resistance mechanisms. To gain a better understanding of stromal biology at the cellular and molecular level in LUAD, we performed single-cell RNA sequencing of 256,379 cells, including 13,857 mesenchymal cells, from 9 treatment-naïve patients. Among the mesenchymal cell subsets, FAP+PDPN+ cancer-associated fibroblasts (CAF) and ACTA2+MCAM+ pericytes were enriched in tumors and differentiated from lung-resident fibroblasts. Imaging mass cytometry revealed that both subsets were topographically adjacent to the perivascular niche and had close spatial interactions with endothelial cells (EC). Modeling of ligand and receptor interactomes between mesenchymal and ECs identified that NOTCH signaling drives these cell-to-cell interactions in tumors, with pericytes and CAFs as the signal receivers and arterial and PLVAPhigh immature neovascular ECs as the signal senders. Either pharmacologically blocking NOTCH signaling or genetically depleting NOTCH3 levels in mesenchymal cells significantly reduced collagen production and suppressed cell invasion. Bulk RNA sequencing data demonstrated that NOTCH3 expression correlated with poor survival in stroma-rich patients and that a T cell-inflamed gene signature only predicted survival in patients with low NOTCH3. Collectively, this study provides valuable insights into the role of NOTCH3 in regulating tumor stroma biology, warranting further studies to elucidate the clinical implications of targeting NOTCH3 signaling.

SIGNIFICANCE:

NOTCH3 signaling activates tumor-associated mesenchymal cells, increases collagen production, and augments cell invasion in lung adenocarcinoma, suggesting its critical role in remodeling tumor stroma.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stromal Cells / Single-Cell Analysis / Tumor Microenvironment / Cancer-Associated Fibroblasts / Receptor, Notch3 / Adenocarcinoma of Lung / Lung Neoplasms / Neoplasm Invasiveness Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Res Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stromal Cells / Single-Cell Analysis / Tumor Microenvironment / Cancer-Associated Fibroblasts / Receptor, Notch3 / Adenocarcinoma of Lung / Lung Neoplasms / Neoplasm Invasiveness Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Res Year: 2024 Document type: Article